10 days of gadget giveaways at Gadling!

AOL Money & Finance

Posts with tag TriumphGroup

Triumph Group (TGI): Shares in bullish 'Cup & Handle' pattern

Triumph Group (NYSE: TGI) designs, engineers, manufactures, repairs, overhauls and distributes aircraft components, such as hydraulic, mechanical and electromechanical control systems, aircraft and engine accessories, structural assemblies, auxiliary power units and aircraft instruments. Customers include original equipment makers and aftermarket manufacturers in the commercial, military, and air cargo markets.

The firm surprised the Street earlier in the month, when it reported Q4 EPS of $1.26 and revenues of $321.2 million. Analysts had been looking for $1.04 and $302.1 million. Management also guided FY08 EPS to $4.85-$5.05 ($4.12 consensus) and FY08 revenues to $1.25-$1.35 billion ($1.13 billion consensus). The CEO noted that quarterly sales had set a new company record and that backlog had reached a record $1.3 billion.

Continue reading Triumph Group (TGI): Shares in bullish 'Cup & Handle' pattern

Analyst initiations: WX, MYGN, CYPB and KNOL

MOST NOTEWORTHY: Aerospace stocks, WuXi Pharma, Myriad Genetics, Cypress Bioscience and Knology were today's noteworthy initiations:
  • LYON initiated shares of aerospace stocks including Goodrich Corporation (NYSE: GR), TransDigm Group Inc (NYSE: TDG) and Triumph Group Incorporated (NYSE: TGI) with Add ratings and a $74 target, $45 target and $90 target, respectively.
  • WuXi Pharmatech (NYSE: WX) was started with a Hold rating and $29 target at Jefferies on valuation. JP Morgan started shares with a Neutral rating and Credit Suisse initiated shares with an Outperform rating.
  • Myriad Genetics Inc (NASDAQ: MYGN) was started with a Hold rating and $50 target at Citigroup, as the firm is cautious on the Phase III Flurizan results and does not recommend putting new money here at these levels.
  • Citigroup also initiated shares of Cypress Biosciences Inc (NASDAQ: CYPB) with a Buy rating and $22 target as the firm believes Milnacipran has sufficient database for approval and is capable of gaining meaningful market share as firstline therapy.
  • Knology Inc (NASDAQ: KNOL) was initiated with a Buy rating and $25 target at BWS Financial, as the firm believes the company's growth potential is greater than other cable companies through a business plan that allows it to have operations in all regions of the U.S.
OTHER INITIATIONS:

Symbol Lookup
IndexesChangePrice

Last updated: November 22, 2008: 08:10 AM

BloggingStocks Exclusives

Hot Stocks

BloggingStocks Featured Video

TheFlyOnTheWall.com Headlines

WalletPop Headlines

AOL Business News

Latest from BloggingBuyouts

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance